PMN ProMIS Neurosciences Earnings per share growth rate in current year

Official company branding of ProMIS Neurosciences, Inc. (PMN)

ProMIS Neurosciences (PMN) operates in secure Western jurisdictions, remaining shielded from geopolitical risks. The YoY EPS trend reflects the current state of earnings, where 77.70 represents the current metric value. Future revenues rely on the rollout of selective antibodies targeting ALS and Alzheimer's. A unique method for combating toxic proteins creates opportunities to establish pricing power.

PMN: promisneurosciences.com Earnings per share growth in current year 06/27/2023 - 11/11/2026

Comprehensive metric breakdowns and analytics for promisneurosciences.com (PMN)

- stock price and consensus target price:
Price Performance Chart ProMIS Neurosciences, Inc.|PMN - Price Target Chart
- market capitalization data:
Market Value ProMIS Neurosciences, Inc.|PMN - Total Company Value
- balance sheet equity data:
Net Assets per Single Share ProMIS Neurosciences|PMN - Company Book Value|Market-to-Book Ratio promisneurosciences.com|PMN - Company Total Assets
- debt and liquidity details:
Debt to Capital Ratio ProMIS Neurosciences|PMN - Long-Term Debt to Equity Ratio|Current Liabilities to Capital ProMIS Neurosciences, Inc.|PMN - Company Debts|Debts to Book Capitalization Ratio ProMIS Neurosciences, Inc.|PMN - Company Long-Term Debt|Company Short-Term Loans and Borrowings ProMIS Neurosciences|Immediate Liquidity promisneurosciences.com
- earnings and valuation multiples information:
PMN - Company Net Income|Future Profit ProMIS Neurosciences|PMN - P/E Multiple|Market Cap to Projected Earnings ProMIS Neurosciences, Inc.|PMN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio ProMIS Neurosciences, Inc.|PMN - Operating profit before deduction of amortization|Earnings per share for the trailing year ProMIS Neurosciences|PMN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months promisneurosciences.com|PMN - Earnings growth in current year|Expected net earnings per share growth next year ProMIS Neurosciences
Basic company analysis:ProMIS PMN
Original product of ProMIS Neurosciences

Valuing the assets of ProMIS Neurosciences (PMN) requires an analysis of earnings per share dynamics. This year-over-year EPS comparison measures the rate of change in net income, reflecting the efficiency of capitalizing scientific achievements. The current value of 77.70 confirms the financial result amid high confidence in Alzheimer's therapy. Growth in this metric signals the monetization of brand image. Ignoring the volatility of this metric could lead to unjustified capital risks.

Main competitors

Jazz Pharmaceuticals PLC - Earnings per share increase in current year|Earnings per share growth in current year Cytokinetics Inc|Earnings per share growth rate in current year PTC Bio PTCT|Earnings per share growth in current year Scholar Rock (SRRK)|Earnings per share growth in current year CNTA (centessa.com)|Earnings per share growth in current year Dyne Therapeutics DYN|Edgewise Therapeutics Inc (EWTX) - Earnings per share growth rate in current year|Rapport Pharma - Earnings growth in current year|Net earnings per share change in current year Alumis Pharma (ALMS)|ZVRA (Zevra Therapeutics) - Net earnings per share growth this year|Earnings per share growth rate in current year contineum-tx.com (CTNM)|Earnings per share growth in current year Larimar Therapeutics, Inc.|Capricor - Earnings per share trend in current year|Earnings per share growth in current year Entrada (TRDA)|PTHS (Channel Pharma) - Earnings per share increase in current year|Earnings per share growth in current year MediciNova MNOV|serinatherapeutics.com (SER) - Earnings per share growth rate in current year|BTAI - Earnings per share growth in current year|Apimeds Pharmaceuticals (APUS) - Net earnings per share growth this year|AEON: Earnings growth in current year|NLSP - Expected net earnings per share growth this year|Earnings per share growth in current year Bionomics Ltd.|fsdpharma.com (HUGE) - Expected net earnings per share growth this year|Net earnings per share growth this year RETA (Reata Pharmaceuticals, Inc.)